The HLA‐B14 Cross‐Reactive Group

Darke, C.

doi:10.1111/j.1399-0039.1980.tb00200.x

Cited by 12 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the B*14:05 and B*14:06 specificities have tenuously been reported as B65, suggesting that epitope 11AV, and motif 8, may play an important role in B65 identity (Table 3), although, in the absence of 97W, it seems likely that both B*14:05 and B*14:06 specificities will both appear as "short" HLA-B14, non-B64/B65. Epitopes 420, 66ITC, 116F, 131S+163T and 170RH and motifs 24 to 29 involve a range of HLA-B specificities (B8, B18, B37, B38, B39, B51, B52, B54 and B55) that are included in the serological HLA-B14 CREG (Darke, 1980b(Darke, , 1983. Thus, these epitopes/motifs give some credence to those early serological findings.…”

Section: Discussionmentioning

confidence: 94%

“…Epitopes 420, 66ITC, 116F, 131S+163T and 170RH and motifs 24 to 29 involve a range of HLA‐B specificities (B8, B18, B37, B38, B39, B51, B52, B54 and B55) that are included in the serological HLA‐B14 CREG (Darke, , ). Thus, these epitopes/motifs give some credence to those early serological findings.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 49 antisera were used to examine the reactivity of the B*14:08:01 product. These were 16 B64, B65 sera (three with some unknown weak reactivity) and 31 B64, B65 antisera with a variety of HLA‐B14 cross‐reactive group (CREG), specificities (Darke, ,b, ). Four of the B14 CREG sera had some additional unknown weak reactivity and four had additional non‐B14 CREG specificities.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Epitopes and motifs of theHLA‐B*14 allele family products and relatedHLA‐B14 cross‐reactive specificities

Street

Darke

2017

Int J Immunogenetics

Self Cite

View full text Add to dashboard Cite

The split specificities of HLA-B14 (B64, B65) are assigned to the B*14:01 (B64) and B*14:02 (B65) products only. Of the further 50 B*14 expressed products, only B*14:03 and B*14:06 are officially designated as HLA-B14. The B*14:08 product differs from B64 by a single amino acid substitution of W97R, while the B*14:53 specificity (which is a "short" B14 and neither B64 nor B65) differs from B64 by three residues (W97S, Y113H and F116Y). Comprehensive testing of B*14:08:01 cells (using 49 alloantisera with B64 or B64, B65 specificities, and five monoclonal antibodies with B65 or B64, B65 activity) showed that the B*14:08 specificity is, like the B*14:53 product, neither B64 nor B65 and appears as a "short" B14 specificity. To help understand the serological reactivity of the B*14:08 and B*14:53 products, and B64 and B65, we identified seven published epitopes (11AV, 97W, 61ICT, 116F, 131S+163T, 170RH and 420) and, by inspection, 29 motifs, that encompass one or more of B64, B65 and various HLA-B14 cross-reactive group specificities. We then considered the possession of these epitopes and motifs by the products of B*14:01 to B*14:06, B*14:08 and B*14:53. Seventeen of the 29 motifs fully complied with the one-/two-patch functional epitope concept for amino acid proximity, as determined by Cn3D software, the remainder partially complied. The nature and patterns of epitopes and motifs possessed by both B*14:08 and B*14:53 specificities supported their designation as HLA-B14 but non-B64/B65. Also that epitope 97W, with 11S or 11A, is critical for serological B64 and B65 reactivity. And conversely, that epitope 116F, and several identified motifs, are probably unimportant for HLA-B14 antibody reactivity. The previous submission that the B*14:03 specificity is HLA-B65 was compatible with its epitope/motif pattern. B*14:04 cells would also be expected to react as B65, based on its epitope/motif pattern, and not as B64 as previously implied. Also, from their epitope/motif patterns, and external serological information, it is probable that the B*14:05 and B*14:06 specificities will both appear as "short" HLA-B14, non-B64/B65. Several epitopes and motifs encompassed a range of HLA-B specificities included in the serological HLA-B14 cross-reactive group, thus supporting these original serological findings.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Epitopes and motifs of theHLA‐B*14 allele family products and relatedHLA‐B14 cross‐reactive specificities

Street

Darke

2017

Int J Immunogenetics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Variations in the B14 "common" determinant could affect the "availability" of a determinant shared by B14 and B38/B39 (allosteric effect (Schwartz et al 1979)). B8 and B39 stimulated antisera that cross-react with B14 are known to react preferentially with Bw65 and Bw64 cells, respectively (Darke 1980b). Differences in antibody binding area or different antibody contact points could also contribute to these findings.…”

Section: Hla-bw6kmentioning

confidence: 99%

“…The HLA phenotypes of the six Bw64 and six Bw65 cell preparations used are shown in Table 2. footnote a. a. Details of these antisera have been described previously (Dewar et al 1977, Darke 1980a, 1980b, 1983a. b. Asshown by the HLA-B type of the antiserum donor's husband.…”

Section: Hla-bi4 Positive Cellsmentioning

confidence: 99%

A F(ab')2 fragment blocking study of the HLA‐B14 antigen

Darke¹

1985

Tissue Antigens

Self Cite

View full text Add to dashboard Cite

The HLA‐B14 antigen exists in two serologically distinct forms termed Bw64 and Bw65. These two B14 subgroups were studied using the ability of F(ab')2 fragments from HLA‐B14 and Bw6 antisera to block the binding of cytotoxic HLA antibodies directed towards the same or an adjacent antigenic site. The findings suggest that the B14 antigen consists of several antigenic determinants some of which are spatially distinct and others which are closely associated. A “common” determinant possessed by both B14 subtypes is proposed which is separate from a Bw64 (or Bw65) site. Additional determinants that B14 shares with B8, B18 and B38/B39 appear to be distinct from the Bw64/Bw65 site, variably associated with the B14 “common” determinant but closely adjoining the Bw6 antigen.

show abstract

HLA‐B*4703: sequence confirmation, serology and distribution

et al. 1999

View full text Add to dashboard Cite

This study has confirmed the nucleotide sequence of exons 2 and 3 of the B*4703 allele, discovered by an unusual HLA-B47 and Bw6 serological pattern, in two subjects of Black/Japanese and Caribbean Black descent. Titration studies on 25 HLA-B47 cross-reactive sera, stimulated by B13, B27, B44 and B60, and nine Bw6 antisera/monoclonal antibodies, showed that the B*4703 product can be distinguished from the established HLA-B47 specificity. The phenotypes of these donors and an International Cell Exchange donor suggests an association between B*4703 and Cw*0701/ 06 in Black subjects. No examples of B*4703 (or B*4702) were found in 10,194 PCR-SSP HLA-A,B typed Welsh Bone Marrow Donor Registry panel members indicating a phenotype frequency of <0.0098% in this primarily Northern European Caucasoid population.

show abstract

The HLA‐B14 Cross‐Reactive Group

Cited by 12 publications

References 20 publications

Epitopes and motifs of theHLA‐B*14 allele family products and relatedHLA‐B14 cross‐reactive specificities

Epitopes and motifs of theHLA‐B*14 allele family products and relatedHLA‐B14 cross‐reactive specificities

A F(ab')2 fragment blocking study of the HLA‐B14 antigen

HLA‐B*4703: sequence confirmation, serology and distribution

Contact Info

Product

Resources

About